Pharmaceutical Patent Challenges: Company Strategies and Litigation Outcomes
Henry Grabowski (),
Anna Taub and
Additional contact information
Henry Grabowski: Duke University
Carlos Brain: Cornerstone Research
Anna Taub: Cornerstone Research
Rahul Guha: Cornerstone Research
American Journal of Health Economics, 2017, vol. 3, issue 1, 33-59
The pharmaceutical industry has experienced a large number of patent challenges in recent years. Key catalysts for this were legal and regulatory changes that awarded 180-day exclusivity rights for first-filing generic firms not only on the basis of a court victory, but also through a settlement with the patent owner. In this paper, we have assembled a unique data set on new drugs approved from 1994 to 2006, including detailed information on patent challenges and litigation outcomes. We find that the new regulatory environment induced significant behavioral changes, including racing by generic firms to challenge patents for large-selling drugs in an environment where more patents are filed by branded firms. Increased generic challenges to different types of patent claims are linked to reduced market exclusivity periods for branded drugs, based on regression analyses and litigation outcomes. Settlements that allow entry prior to patent expiry are a prevalent litigation outcome given the risks of an unfavorable court decision that can adversely affect a company's market valuation. This topic remains an important issue for further research, particularly given different public policies governing patent challenges for biosimilars and biologics compared with those for generic drugs and new chemical entities.
Keywords: pharmaceuticals; Hatch-Waxman Act; patent challenges; market exclusivity; generic competition (search for similar items in EconPapers)
JEL-codes: D22 I18 K20 L65 O30 (search for similar items in EconPapers)
References: Add references at CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Access to the online full text or PDF requires a subscription.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ucp:amjhec:v:3:y:2017:i:1:p:33-59
Access Statistics for this article
More articles in American Journal of Health Economics from University of Chicago Press
Bibliographic data for series maintained by Journals Division ().